Interview with Dr. Matthew Milowsky of the Academic Urology Research Investigators Consortium (AURIC)

Dr. Matthew Milowsky joins Sam Chang in a discussion on the patient-reported outcomes from Cohort K of the EV-103 Phase 1b/2 study which analyzed the impact of enfortumab vedotin (EV) alone or combined with pembrolizumab on patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin. The objective was to describe the impact on the patients’ quality of life (QoL), functioning, and symptoms.

The combination of EV and pembrolizumab demonstrated an objective response rate of 64.5%, whereas EV monotherapy had an objective response rate of 45.2%. The quality of completion rates for questionnaires at baseline was ≥84% through Week 24. Patients who received the combination of EV and pembrolizumab showed improvement or preservation of QoL and functioning scale scores. Clinically meaningful improvements in pain, insomnia, and constipation were seen, and worst pain improved at Week 24.

Recommended Posts